How much profit has Zai Lab made this year?
Zai Lab has made -308.35 M USD this year.
Zai Lab Net Income 2024
Zai Lab Net Income
-308.35 M USD
Ticker
9688.HK
ISIN
KYG9887T1085
WKN
A2DX7H
In 2024, Zai Lab's profit amounted to -308.35 M USD, a -7.85% increase from the -334.62 M USD profit recorded in the previous year.
The Zai Lab Net Income history
| YEAR | NET INCOME (undefined USD) |
|---|---|
| 2029e | 6.13 |
| 2028e | 3.96 |
| 2027e | 1.9 |
| 2026e | 0.11 |
| 2025e | -0.19 |
| 2024e | -0.31 |
| 2023 | -0.33 |
| 2022 | -0.44 |
| 2021 | -0.7 |
| 2020 | -0.27 |
| 2019 | -0.2 |
| 2018 | -0.14 |
| 2017 | -0.05 |
| 2016 | -0.04 |
Zai Lab Revenue, EBIT, Net Income KYG9887T1085 · A2DX7H
3 years
5 years
10 years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into Zai Lab, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Zai Lab from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Zai Lab’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of Zai Lab. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into Zai Lab’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing Zai Lab’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Zai Lab’s growth potential.
Zai Lab Revenue, EBIT and net profit per share
| Date | Zai Lab Revenue | Zai Lab EBIT | Zai Lab Net Income |
|---|---|---|---|
| 2029e | 2.19 B undefined | 0 undefined | 6.13 B undefined |
| 2028e | 1.74 B undefined | 444.14 M undefined | 3.96 B undefined |
| 2027e | 1.32 B undefined | 199.68 M undefined | 1.9 B undefined |
| 2026e | 933.1 M undefined | -13.03 M undefined | 107.84 M undefined |
| 2025e | 589.53 M undefined | -219.59 M undefined | -190.4 M undefined |
| 2024e | 394.44 M undefined | -340.06 M undefined | -308.35 M undefined |
| 2023 | 266.72 M undefined | -376.57 M undefined | -334.62 M undefined |
| 2022 | 215.04 M undefined | -404.36 M undefined | -443.29 M undefined |
| 2021 | 144.3 M undefined | -700.1 M undefined | -704.5 M undefined |
| 2020 | 49 M undefined | -301.8 M undefined | -268.9 M undefined |
| 2019 | 13 M undefined | -203.2 M undefined | -195.1 M undefined |
| 2018 | 100,000 undefined | -141.8 M undefined | -139.1 M undefined |
| 2017 | 0 undefined | -51.4 M undefined | -50.4 M undefined |
| 2016 | 0 undefined | -38.5 M undefined | -37.5 M undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2016 | 0 USD | -38.5 M USD | -37.5 M USD |
| 2017 | 0 USD | -51.4 M USD | -50.4 M USD |
| 2018 | 100,000 USD | -141.8 M USD | -139.1 M USD |
| 2019 | 13 M USD | -203.2 M USD | -195.1 M USD |
| 2020 | 49 M USD | -301.8 M USD | -268.9 M USD |
| 2021 | 144.3 M USD | -700.1 M USD | -704.5 M USD |
| 2022 | 215.04 M USD | -404.36 M USD | -443.29 M USD |
| 2023 | 266.72 M USD | -376.57 M USD | -334.62 M USD |
| 2024e | 394.44 M USD | -340.06 M USD | -308.35 M USD |
| 2025e | 589.53 M USD | -219.59 M USD | -190.4 M USD |
| 2026e | 933.1 M USD | -13.03 M USD | 107.84 M USD |
| 2027e | 1.32 B USD | 199.68 M USD | 1.9 B USD |
| 2028e | 1.74 B USD | 444.14 M USD | 3.96 B USD |
| 2029e | 2.19 B USD | 0 USD | 6.13 B USD |
Zai Lab stock margins KYG9887T1085 · A2DX7H
The Zai Lab margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Zai Lab. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Zai Lab.
3 years
5 years
10 years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the Zai Lab's sales revenue. A higher gross margin percentage indicates that the Zai Lab retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the Zai Lab's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the Zai Lab's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Zai Lab's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Zai Lab. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Zai Lab's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Zai Lab Margin History
| Zai Lab Gross margin | Zai Lab Profit margin | Zai Lab EBIT margin | Zai Lab Profit margin |
|---|---|---|---|
| 2029e | 64.08 % | 0 % | 279.25 % |
| 2028e | 64.08 % | 25.45 % | 227.11 % |
| 2027e | 64.08 % | 15.18 % | 144.54 % |
| 2026e | 64.08 % | -1.4 % | 11.56 % |
| 2025e | 64.08 % | -37.25 % | -32.3 % |
| 2024e | 64.08 % | -86.21 % | -78.18 % |
| 2023 | 64.08 % | -141.19 % | -125.46 % |
| 2022 | 65.58 % | -188.04 % | -206.14 % |
| 2021 | 63.83 % | -485.17 % | -488.22 % |
| 2020 | 65.71 % | -615.92 % | -548.78 % |
| 2019 | 70.77 % | -1,563.08 % | -1,500.77 % |
| 2018 | 100 % | -141,800 % | -139,100 % |
| 2017 | 64.08 % | 0 % | 0 % |
| 2016 | 64.08 % | 0 % | 0 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2016 | 64.08 % | 0 % | 0 % |
| 2017 | 64.08 % | 0 % | 0 % |
| 2018 | 100 % | -141,800 % | -139,100 % |
| 2019 | 70.77 % | -1,563.08 % | -1,500.77 % |
| 2020 | 65.71 % | -615.92 % | -548.78 % |
| 2021 | 63.83 % | -485.17 % | -488.22 % |
| 2022 | 65.58 % | -188.04 % | -206.14 % |
| 2023 | 64.08 % | -141.19 % | -125.46 % |
| 2024e | 64.08 % | -86.21 % | -78.18 % |
| 2025e | 64.08 % | -37.25 % | -32.3 % |
| 2026e | 64.08 % | -1.4 % | 11.56 % |
| 2027e | 64.08 % | 15.18 % | 144.54 % |
| 2028e | 64.08 % | 25.45 % | 227.11 % |
| 2029e | 64.08 % | 0 % | 279.25 % |
Zai Lab Aktienanalyse
What does Zai Lab do?
Zai Lab Ltd is a biotech company based in Shanghai, China, that focuses on the development and commercialization of innovative drugs and therapies for unmet medical needs. The company's history dates back to 2014 when Dr. Samantha Du, an experienced pharma executive, founded the company to realize her vision of a modern, science-based biotech company in China. Zai Lab's business model is based on several strategic pillars. On one hand, the company collaborates with leading pharma and biotech research centers to discover, develop, and market new active ingredients and therapies. On the other hand, Zai Lab also promotes the acquisition of promising companies and technologies to strengthen its innovative power and expand its product portfolio. Another important aspect of Zai Lab's business model is its close collaboration with the Chinese government and healthcare system to simplify and improve access to new drugs and therapies for patients in China. Zai Lab operates in various business areas and markets to cover a wide range of medical needs. One of Zai Lab's main areas is oncology pharmaceuticals used to treat cancer. The company has focused primarily on novel active ingredients that have the potential to selectively target certain types of cancer cells while sparing healthy cells. Zai Lab's key oncology products include Niraparib, a PARP inhibitor for the treatment of ovarian cancer, and ZL-2301, a SHRPI inhibitor for the treatment of liver and lung cancer. Another important business area for Zai Lab is immunology and autoimmunity. Here, the company develops new therapies and medications that can modulate and regulate the immune system in certain disease conditions. One of the most promising products is the drug FOLFIRINOX, an immunomodulator for the treatment of chronic inflammatory bowel diseases. In addition to oncology and immunology, Zai Lab is also involved in other areas of medicine such as gastroenterology, infectious diseases, and neuroscience. In these fields, the company develops new antibiotics, vaccines, and medications for the treatment of diseases such as hepatitis B, Lyme disease, and Alzheimer's. Overall, Zai Lab aims to improve the health and well-being of patients in China and worldwide through its broad product range and innovation power. In recent years, Zai Lab has written an impressive growth story. The company has raised several million dollars in investments since its inception and has built a strong network and collaboration with other companies. Recently, Zai Lab has also attracted additional investors through IPOs in Hong Kong and New York, further strengthening its position as a leading biotech company in China. Overall, Zai Lab is an emerging biotech company that aims to fulfill medical needs in China and worldwide with its broad range of products and services and its innovation power. The company relies on close collaboration with leading research centers, companies, and government agencies, and strives to improve the health and well-being of patients worldwide. Zai Lab ist eines der beliebtesten Unternehmen auf Eulerpool.com.Net Income Details
Understanding Zai Lab's Profit Margins
The profit margins of Zai Lab represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of Zai Lab's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.
Year-to-Year Comparison
Evaluating Zai Lab's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.
Impact on Investments
Zai Lab's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.
Interpreting Profit Fluctuations
When Zai Lab’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.
Frequently Asked Questions about Zai Lab Stock
How has the profit developed compared to last year?
The profit has increased by -7.85% compared to last year fallen
What impact do the earnings have on the shareholders?
An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.
How does Zai Lab publish its earnings?
Zai Lab publishes its earnings in the form of quarterly or annual reports.
Which financial indicators are included in the quarterly or annual reports?
The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.
Why is it important for investors to know the earnings of Zai Lab?
The profits of Zai Lab are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.
How can one learn more about the earnings of Zai Lab?
You can learn more about the earnings of Zai Lab by reviewing the quarterly or annual reports or following the company presentations.
How much dividend does Zai Lab pay?
Over the past 12 months, Zai Lab paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Zai Lab is expected to pay a dividend of 0 USD.
What is the dividend yield of Zai Lab?
The current dividend yield of Zai Lab is .
When does Zai Lab pay dividends?
Zai Lab pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Zai Lab?
Zai Lab paid dividends every year for the past 0 years.
What is the dividend of Zai Lab?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Zai Lab located?
Zai Lab is assigned to the 'Health' sector.
Wann musste ich die Aktien von Zai Lab kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Zai Lab from 7/1/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 7/1/2024.
When did Zai Lab pay the last dividend?
The last dividend was paid out on 7/1/2024.
What was the dividend of Zai Lab in the year 2023?
In the year 2023, Zai Lab distributed 0 USD as dividends.
In which currency does Zai Lab pay out the dividend?
The dividends of Zai Lab are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Zai Lab
Our stock analysis for Zai Lab Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Zai Lab Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
